Hormonal
GLP-1 receptor agonists (GLP1RAs) do not increase the risk of adverse events compared to other anti-obesity medications in patients who have undergone bariatric surgery.
If you have had bariatric surgery and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight regain, current data indicates they are not more dangerous than other standard weight loss drugs. The risk of serious complications is low and similar to other options. However, starting these medications more than 12 months after surgery appears to have a lower risk of adverse events than starting them earlier.
GLP1RAs were not associated with an increased risk of AEs compared to non-GLP1RA AOMs in patients who previously underwent bariatric surgery.
Why this rating
Retrospective cohort study with large sample size (n=599) but inherent observational biases and lack of dosing data.
Source
Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery
Jason M. Samuels et al. · medRxiv · 2024
DOI 10.1101/2024.04.21.24306138
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →